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Summary
Studies using in vitro cell models enable evaluation
of the effects of different PRP products under very
controlled and standardized conditions. Therefore
the results of such studies build the basis for un-
derstanding the variable results of clinical studies
on the use of PRPs. The main lessons learned
through the use of in vitro cell models are that
many different PRP products exist and researchers
have to report on component variation within each
product. These different products may have distinc-
tive effects on the various cells treated in muscu-
loskeletal injuries; therefore, some products might
be more beneficial in certain indication than others.
In its utilization in cell models, PRP may generate a
variety of positive effects on cell proliferation, re-
covery, and inflammatory response. There might al-
so be a benefit to adding PRP to current pharmaco-
logical therapies (e.g. corticosteroids) to prevent
their commonly known negative effects on e.g. ten-
don and cartilage tissue.
KEY WORDS: platelet-rich plasma, PRP, tendon, teno-
cytes, in vitro.
Introduction
Platelet-rich concentrates, especially platelet-rich
plasma (PRP), have shown promising results for the
treatment of various musculoskeletal injuries1,2. Most
of these results are based on either basic research or
animal studies. However, recent clinical studies re-
porting on a higher level of evidence fail to show con-
sistent positive results for the use of various PRPs.3
Since the first reports on the use of PRPs in medicine
in the late 1980’s, specifically in cardiac surgery, a
plethora of different production methods for PRPs
have been published in the literature or presented by
medical companies4. This results in numerous PRP
products, which differ in terms of platelet number,
white blood cell content, fibrin concentration, and
method of platelet activation5. Finally, the only con-
stant factor for all of these products could be seen in
the definition by Marx6, who stated in 2001 that a
platelet concentrate is called a PRP if the platelet
concentration is above the baseline.
This variability forces us to get back to methods of
standardized basic research testing to evaluate the
basic properties and principles regarding the effects
of PRP on the cells in the targeted tissue7. Therefore,
this paper is intended to report on the lessons we
have learned through translational research methods
and focuses on the detection of the significant differ-
ences found in the distinctive PRP products and their
effects on cells, tested in standardized in vitro envi-
ronments. This is acknowledged as the best method
to evaluate these differences without the variability of
in vivo testing.
Variability of PRP products 
PRP is produced by two basic methods following cen-
trifugation of whole blood: separation of the buffy coat
layer or isolation of the plasma layer. Buffy coat
preparations are designed to retain the maximum
number of platelets, and also include a higher con-
centration of leukocytes as well as some residual ery-
throcytes. High centrifuge spin rates for long dura-
tions are used to generate buffy coat preparations,
whereas plasma-based products are prepared using
a slower centrifugation rate over a shorter period of
time. As a result, plasma-based PRPs contain fewer
platelets, but are generally devoid of both white and
red blood cells. Whether there is an advantage or
detriment to leukocyte inclusion in PRP remains a
matter of debate1,8.
The varying methods employed for PRP production
may be a basis for the inconclusive results observed in
clinical studies evaluating the efficacy of PRP treat-
ment. Therefore, it is highly important for the clinician to
be mindful of the different ways to obtain PRP, and how
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the differing approaches affect the composition of PRP
at the time of treatment. To classify the numerous pro-
duction methods, integrated systems are needed to
better categorize PRP according to its principal con-
tents (platelet concentration, leukocyte concentration,
etc.). Several categorization methods have been pro-
posed; however, to date, a standardized classification
system has yet to be implemented in common practice.
Dohan Ehrenfest et al.5 reported on a classification of
platelet concentrates, which sorted the products ac-
cording to their platelet, fibrin and leukocyte concen-
tration: pure platelet-rich plasma (P-PRP), leukocyte-
and platelet-rich plasma (L-PRP), pure platelet-rich
fibrin (P-PRF), and leukocyte- and platelet-rich fibrin
(L-PRF). These classifications were based on three
sets of parameters: 1) the functional aspect of prepa-
ration, including the type of centrifuge used, duration
of spin, and cost of preparation; 2) the final volume of
PRP produced and degree of platelet and leukocyte
retention and preservation following centrifugation;
and 3) the fibrin density and organization following
fibrinogen activation and clot formation. Only the sec-
ond and third parameters were used for the classifi-
cation of PRP and PRF. Therefore, this system sorts
different preparations on the basis of leukocyte inclu-
sion and fibrin clot presence with consideration of the
facility and cost-effectiveness of individual systems. 
De Long et al.9 presented the P.A.W. classification
system, which was based on the method of platelet
activation in addition to platelet concentration and
presence or absence of white blood cells, and there-
fore represented a more detailed method. Platelet
concentrations were grouped into four categories in
relation to physiologic baseline, normally between
150,000-300,000 platelets/μl in whole blood, depend-
ing on the individual. A P1 classification corresponds
to preparations with platelet levels below this base-
line, and such preparations are generally termed
platelet-poor plasma (PPP). P2 describes a moderate
platelet concentration up to four times the physiologic
concentration. Most plasma-based PRP products fall
into the P2 category. P3 describes a high concentra-
tion between four and six times baseline platelet lev-
els. Buffy coat systems typically generate platelet
concentrations in the P3 range. Finally, P4 desig-
nates any concentration greater than six times physi-
ologic platelet levels. Products in the P4 category
may actually hinder the healing process due to
growth factor overload, and as a whole are largely not
recommended for therapeutic use (Choi et al.10). This
system further distinguishes if platelets are activated
prior to PRP administration, either exogenously using
thrombin and calcium chloride or endogenously via
Type I collagen present at the injection site. The
presence of white blood cells is characterized as ei-
ther being above (A) or below (B) baseline leukocyte
counts. Generally, buffy coat preparations have an
“A” designation for this category while plasma-based
products are classified as “B”. Overall, this classifica-
tion provides a useful categorization of the important
components of PRP, which can help direct the clini-
cian’s therapeutic approach. 
Compounding the inconsistency between preparation
methods are the inherent variations caused by physio-
logical fluctuations in blood composition11. Naturally,
blood from one patient may have a very different com-
position from another, but blood from an individual pa-
tient can also vary greatly between each draw. There-
fore, the final PRP product is ultimately determined by
the nature of the patient’s blood at the time of draw. 
Our group12 reported a high degree of variability be-
tween subjects and within individual PRP samples
prepared after three separate blood draws spaced
two weeks apart. The study evaluated a plasma-
based system: the Arthrex ACP Double Syringe
(Arthrex Inc., Naples, FL, USA) and a buffy coat-
based system: the Biomet GPS III Platelet Concen-
trate Separation Kit (Biomet Inc., Warsaw, IN, USA).
Intra-individual platelet counts showed wide differ-
ences for each of the three preparations, indicating
that variability persists even for PRP prepared using
the same system on the same patient over time. The
mean platelet count for the plasma-based system
(378.3 ± 58.64 x 103 platelets/μl) was significantly
lower than that of the buffy coat system (873.8 ±
207.82 x103 platelets/μl). Leukocyte count was also
significantly reduced in the plasma preparation (0.6 ±
0.3 x 103/μl) compared with buffy coat preparation
(20.5 ± 6.7 x 103/μl), which was nearly four times
above the mean whole blood white blood cell count
(5.6 ± 1.7 x 103/μl). 
Sundman et al.13 also evaluated the Arthrex and Bio-
met systems and reported results similar to Mazzoc-
ca et al. for platelet (361 ± 87.0 x 103/μl) and leuko-
cyte (0.68 ± 0.42 x 103/μl) counts for the Arthrex plas-
ma-based system. Results from the Biomet buffy
coat-derived system differed slightly: (701 ± 473 x
103 platelets/μl) and (23.7 ± 5.91 x 103 leukocytes/μl).
These findings differed from those of Castillo et al.4,
who also evaluated the Biomet GPS III along with
other systems and reported somewhat contrasting re-
sults from the previously mentioned studies. The
platelet count from the buffy coat-based system was
fairly lower (566.2 ±292.6 x 103/μl) while the leuko-
cyte count (34.4 ± 13.6 x 103/μl) was much higher
than the two other reports. It is important to point out
that all three studies mentioned here presented
platelet counts with relatively high standard devia-
tions, further alluding to the large variability between
PRP preparations. Figure 1 illustrates differences be-
tween platelet and leukocyte content in plasma- and
buffy coat-based systems. 
Effects of different PRPs on musculoskeletal
target cells
The use of PRP to augment the healing of muscu-
loskeletal injuries is only beneficial if the contents have
advantageous effects on the tissue-specific cells of the
injured site. Therefore, it is important to know the spe-
cific effects of the various contents of PRP on these tar-
get cells. PRP contains high concentrations of growth
factors including platelet-derived growth factor (PDGF),
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transforming growth factor beta (TGF-β), vascular en-
dothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF), hepatocyte growth factor (HGF), and
epidermal growth factor (EGF) that provide the poten-
tial to modulate the healing of bone, muscle, and ten-
don through interactions with specific cells in these re-
spective structures14 (Fig. 2). An overview of the effect
of these growth factors and secretory proteins on mus-
culoskeletal target cells specifically related to bone,
muscle, and tendon will be covered in this section.
The process of bone regeneration involves a series of
events dependent on resident bone cells and the ex-
tracellular environment that includes mesenchymal
stromal cells (MSCs), growth factors, and vascular
structures15,16. PRP contains pro-osteogenic factors
including PDGF, TGF-β, EGF, VEGF, and bFGF that
may play a critical role in the process of bone regen-
eration15,17. These factors make PRP a potential ther-
apeutic agent to be used either alone or in combina-
tion with MSCs to regenerate bone15,18-21. For muscu-
lar injuries, specific growth factors involved in repair
are not completely understood at the present time;
however the effects of growth factors present in PRP
are believed to have the potential to improve healing
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Figure 1. Different methods for
PRP production shown according
to their platelet und leukocyte con-
centration reported in recent stud-
ies. Please note that most “buffy
coat” based procedures utilize a
double spin centrifugation12,13.
Figure 2. Examples of human ten-
don like cells grown in standard
culture medium were treated at the
same time with different PRP prod-
ucts (single spin PRP with platelet
concentration of 324 ± 28.7 x
103/μL and double spin PRP with
platelet concentration of 555 ± 67.3
x 103/μL) vs fetal bovine serum
(FBS) controls. Cells treated with
2% FBSare viable but in a non-pro-
liferative state compared to cells
treated with normal control medium
(10% FBS) which promotes prolif-
eration. Cells treated with 2% FBS
and Single and Double Spin PRP
preparations show a significant in-
crease in proliferation compared to
cells treated with 2 and 10% FBS
alone. Cells treated with Single
Spin PRP reached a state of con-
fluence more rapidly than the other
treatment groups. (Mag = 10x).
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and clinical outcomes14. The underlying basis of this
proposed benefit is that a muscle contusion, strain, or
laceration undergoes a repair process that includes
three overlapping phases – inflammation, regenera-
tion, and repair, followed by fibrosis and remodel-
ing14,22-24. The transition between phases of this repair
process is controlled by PDGF, bFGF, TGF-β, and
HGF14,25,26. Based on the presence of these growth
factors and the key roles they play in the muscular re-
pair process, the therapeutic goal of PRP for muscular
injury is to shorten the sequence of the healing cas-
cade14. Similar to its effects on muscle healing, the in-
trinsic properties of PRP also regulate the phases of
tendon healing. The effects that growth factors have
on tendon healing are still under investigation; howev-
er, it is possible that the intrinsic characteristics of
PRP may augment the healing process13,14.
Our group evaluated the effects of three different
PRP products on the proliferation of osteoblasts, my-
oblasts, and tenocytes. Comparing a single-spin
process yielding low platelet and white blood cell con-
centration, a single-spin process yielding high platelet
and white blood cell concentrations, and a double-
spin process that produces a high platelet concentra-
tion and low white blood cell concentration, the au-
thors observed increases in proliferation for each tar-
get cell (bone, muscle, and tendon) across all meth-
ods of procurement27. Based on the results, we were
able to conclude that the application of various PRP
separations may result in a potentially beneficial ther-
apeutic effect on clinically relevant target cells27. Al-
though the study reported on the potentially beneficial
effects of PRP on target cells, we acknowledged that
it remains unclear as to which platelet concentration
or PRP preparation is considered the optimal treat-
ment of various cell types and that a “more is better”
theory for the use of higher platelet concentrations
could not be supported27.
Anitua et al.28 evaluated the effects of scaffolds pre-
pared from preparations rich in growth factors
(PRGF) with increasing amounts of platelets (low
number of leukocytes) on fibroblast cell cultures har-
vested from three different anatomical sites (skin,
synovium and tendon). They observed an increase in
cell proliferation for all PRGF types and preparations
(even including the supernatans of platelet poor plas-
ma) compared to the controls. However, adding scaf-
folds containing a platelet concentration of 2-4x
above baseline resulted in the highest proliferation
rate. In addition, fibroblasts harvested from different
origins demonstrated variable angiogenic responses
with regards to their anatomical origin.
Proliferation assays are used for most in vitro cell
models, since this assay is directly linked to DNA pro-
duction within cells and closely correlated with cell di-
vision, therefore demonstrating proliferative activity.
Proliferation of tenocyte-like cells was affected posi-
tively by the addition of PRP products in a number of
in vitro studies evaluating tendon-like cells29-32. How-
ever the in vitro models fail to conclusively show if
this increased proliferation has positive or negative
effects. 
The type I to type III collagen ratio is seen as an im-
portant aspect for successful regeneration of func-
tional tendon tissue. A recent review performed by
Baksh et al.33 identified nine studies overall showing
an increase in this collagen ratio and two explicit
studies, which reported an improved collagen I/III ra-
tio compared to the controls.
More recently, Perut et al.15 investigated the efficacy
of different components of platelet concentrates on
the osteogenic differentiation of bone marrow stromal
cells (BMSCs). Comparing two different procurement
techniques, the authors reported that, in addition to
the differences in platelet recovery between systems,
the composition of PRP was associated with variance
in the progressive release of bFGF from the platelet
gel, which is significantly associated with the prolifera-
tion of BMSCs and their ability to mineralize15. Based
on the results of their work, the authors concluded
that the ability of different platelet gels to induce prolif-
eration and osteogenic differentiation of BMSCs is re-
lated to the composition of PRP including the platelet,
leukocyte, and growth factor concentrations and avail-
ability15. The investigators suggest that, based on the
data presented in their study, composition and bioac-
tivity of PRP should be analyzed so that the clinician
has a more complete understanding of the potential
effectiveness of the regenerative treatment15.
Anti-inflammatory effects of PRP
Chronic or acute inflammation of the joint, whether it be
through injury or disease such as osteoarthritis (OA),
can be debilitating. A wide spectrum of treatments are
available, from non-pharmacological modalities to di-
etary supplements and pharmacological therapies, as
well as minimally invasive procedures involving injec-
tions of various substances aimed at restoring joint
homeostasis and providing clinical improvement and
possible disease modifying effects34-45. These injec-
tions are sometimes painful and are oftentimes com-
bined with local anesthetics to alleviate the discomfort
of the injection. 
As an autologous blood product, PRP provides a
promising alternative to steroid injections by promot-
ing safe and natural healing. PRP is a rich source of
growth factors, but it also contains antibacterial and
fungicidal proteins, metalloproteinases (MMPs), co-
agulation factors, and membrane glycoproteins that
influence inflammation by inducing the synthesis of
other integrins, interleukins, chemokines, and cy-
tokines46. Muscles, tendons, and ligaments heal by
going through three phases of wound healing - in-
flammation, proliferation and remodeling; various cy-
tokines are active during each of these phases of
wound healing2,47-49. The cytokines and other bioac-
tive factors released from PRP are known to affect
these basic metabolic processes in the soft tissues of
the musculoskeletal system2,47-49.
Although there have been many clinical studies on the
anti-inflammatory effects of corticosteroids injections,
clinical studies using PRP are limited39,50-54. Studies
Muscles, Ligaments and Tendons Journal 2014; 4 (1): 38-45 41
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such as these require time, resources, and a large pa-
tient pool to draw from, making in vitro studies very at-
tractive to answer basic science questions. In vitro
studies assessing PRP’s anti-inflammatory effects,
however, are difficult because clinical benefits may not
be directly correlated to in vitro results. Because of the
wide variation of injection and PRP preparation meth-
ods used in clinical settings, it is difficult to determine
the exact levels of growth factors found in or around
cartilage and tendon tissue in the human body55. Al-
though there have been in vitro studies assessing the
anti-inflammatory effects of PRP, few have directly ad-
dressed PRP’s effects on chondrocytes or tenocytes.
A recent review article by Filardo et al. reported 17 in
vitro studies in which the role of PRP on chondrocytes
were investigated, of which only 4 papers focused on
PRP in OA chondrocytes for modulation of inflamma-
tion35,56-59. One reason for the lack of studies may the
difficulty in recreating a state of inflammation in either
chondrocyte or tenocyte cultures.
One of the most recent and interesting in vitro studies
conducted by Sundman et al. assessed the anti-in-
flammatory effects of PRP and high molecular weight
hyaluronan (HA) in an ex vivo co-culture model for
OA using human cartilage and synovium60. Their re-
sults showed that tumor necrosis factor α (TNF-α), a
mediator of acute inflammation and an activator of
MMPs, was decreased in the media of the PRP and
HA groups compared to the control group61-63. MMP-
13 gene expression in synoviocytes was significantly
decreased in the PRP group but not the HA group,
while hyaluronan synthase 2 (HAS-2) expression in
the synovium was increased by the addition of PRP
compared to the HA and control groups. Further, car-
tilage matrix gene expression of aggrecan and type I
collagen in the collagen explants treated with PRP
was significantly higher than in the HA groups but not
from the control untreated group. Combined, these
results suggest that PRP can act to stimulate en-
dogenous HA production while decreasing cartilage
catabolism. They concluded that PRP can act to sup-
press inflammatory mediator concentration and gene
expression in synovium and cartilage tissue.
An in vitro study by El-Sharkawy et al. used mono-
cyte culture to assess cytokine and chemokine levels,
as well as monocyte chemotactic migration, in the
presence and absence of PRP64. Their results
showed that monocyte chemotactic protein-1 (MCP-
1), which is released by monocytes in response to
pro-inflammatory stimuli, was significantly decreased
by PRP in monocyte culture compared to untreated
cells. However, chemokine ligand 5 (CCL5), also
known as RANTES (regulated on activation, normal T
cell expressed and secreted), was significantly in-
creased compared to control untreated cells and led
to a dose-dependent increase in monocytechemo-
taxis. In addition, levels of lipoxin A4 (LXA4), an anti-
inflammatory lipid, were significantly higher in PRP
compared to those in whole blood. This study sug-
gests that PRP can act as an anti-inflammatory agent
by producing endogenous anti-inflammatory factors
and by affecting monocyte cytokine release. 
Our lab recently completed an in vitro study in which
we assessed the anti-inflammatory effects of PRP, ei-
ther alone or in combination with the corticosteroid
methylprednisolone or the NSAID ketorolac
tromethamine, on stimulated human umbilical vein
endothelial cells (HUVECs)55. The cells were first
stimulated with inflammatory cytokines: TNFα and in-
terferonγ (INFγ), after which cell adhesion molecule
expression for E-selectin, vascular cell adhesion mol-
ecule (VCAM), and human leukocyte antigen DR
(HLA-DR) were measured. The results showed a de-
creased expression of cell adhesion molecules in
stimulated cells after treatment with PRP, ketorolac,
and methylprednisolone, with methylprednisolone
having the greatest anti-inflammatory effect. Addition-
ally, there were no significant differences seen be-
tween PRP and ketorolac, suggesting that PRP and
ketorolac have a similar inhibitory effect on the in-
flammatory process in stimulated HUVECs. Although
a decrease in inflammation was observed in this pa-
per, the in vitro behavior of HUVECs may not mimic
the in vivo environment surrounding the joint, making
this one of the limitations of this paper. However, this
is a commonly used model for general inflammation.
We concluded that both PRP and ketorolac reduced
cellular inflammation compared to control, but neither
caused as great a reduction as methylprednisolone.
As stated earlier, the composition of different PRP
products differs significantly in terms of leukocyte con-
tent. This might also affect the PRPs’ anti-inflammato-
ry effects. Mc Carrell et al. (JBJS, 2012) demonstrat-
ed, using tendon-like cells harvested and cultured
from horse flexor digitorum superficialis tendons, that
an increase in leukocyte content of PRP products is
positively correlated with an increased expression of
inflammatory cytokines and that the platelet/leukocyte
ratio had no influence on this effect.
Discussion
Studies using in vitro cell models enable evaluation of
the effects of different PRP products under very con-
trolled and standardized conditions. Therefore the re-
sults of such studies build the basis for understanding
the variable results of clinical studies on the use of
PRPs. However, all of the results of such in vitro
models have to be evaluated with caution, since the
final clinical effects are not proven1-3,33.
We have learned from these controlled laboratory
studies that PRP products can vary greatly, even in
such basic aspects as their platelet concentration or
the content of white blood cells12,13. Recent classifica-
tion methods have been established to allow the clini-
cian to exactly report on the nature of the specific PRP
product used in their study. Out of these, De Long´s
classification allows for a very detailed distinction of
the various PRP production methods, whereas the
classification presented by Dohan Ehrenfest describes
fibrin contents in more detail5,9. Besides these overall
classifications, studies have shown a high intra-individ-
ual variability of PRP products, even if these have
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K. Beitzel et al.
©
 C
IC
 Ed
izi
on
i I
n
e
na
zi
na
li
been isolated from an identical subject12. Therefore the
optimal methodology for clinical studies would be at
least to report on the individual platelet- and white
blood cell concentration of each treatment used in clin-
ical studies11-13. This would allow for better comparison
between studies and more accurate overall conclu-
sions on the effects of the different PRP products.
Multiple studies utilized tendon-like cell models33.
Most of the reported studies showed increased cell
proliferation with the addition of various PRP prod-
ucts. This suggests that PRP products have a positive
effect on the cells’ mitogenic activity. Also, improve-
ment in collagen production and optimization of the
important collagen I/III ratio have been ob-
served29,31,33. However, these positive effects and
their consequences for “real life” tissue healing have
yet to be identified in clinical studies3. It has also been
shown, that different cell types (e.g. tendon-like cells
vs. osteoblasts) show varying results if different PRP
products are applied to the cell culture28,29. This raises
the question if the variation of PRP components may
allow for a targeted use of the specific product (e.g.
high concentration of platelets vs low concentration)
for a specific cell type. This means, for example, ten-
don cells may benefit from one type of PRP product
for the treatment of tendinitis whereas chondrocytes
and synovial cells may benefit from a different PRP
product for the treatment of cartilage lesions or joint
inflammation. Knowledge about these specific func-
tions is only just emerging and many additional stud-
ies are needed to finally understand these potential
relationships.
All in vitro studies have multiple limitations and con-
clusions drawn from these studies can only be trans-
ferred into the clinical setting with much caution. Most
of the cited studies utilized different donors for the
cell culture and the PRP products. In general, PRPs
are intended to be an autologous treatment. There-
fore, unknown immunological effects cannot be totally
ruled out in such in vitro experiments. This might be
of special importance for the studies evaluating PRP
products with a high concentration of white blood
cells. As stated earlier, only specific functions of the
cells, such as cell proliferation and production of ma-
trix proteins (e.g. collagen), are assayed in such in
vitro models, which limits the conclusions about these
factors and does not allow for a clinical prognosis. On
the other hand, in vitro cell models allow for a very
standardized and controlled set up, which enables
strict evaluation of a specific question without signifi-
cant variability due to the environment.
Overall, these in vitro studies give a broad basis for
future clinical studies, which should take the present-
ed findings into account and adapt the methodology
according to the lessons we have learned from in vit-
ro studies.
Conclusion
In summary, the main lessons learned through the
use of in vitro cell models are that many different
PRP products exist and researchers have to report
on component variation within each product. These
different products may have distinctive effects on the
various cells treated in musculoskeletal injuries.
Therefore, some products might be more beneficial in
certain indication than others. In its utilization in vitro
models, PRP may generate a variety of positive ef-
fects on cell proliferation, recovery, and inflammatory
response. There might also be a benefit to adding
PRP to current pharmacological therapies (Corticoids
or NSAIDs) to prevent their commonly known nega-
tive effects on tendon and cartilage tissue.
The University of Connecticut Health Center / New
England Musculoskeletal Institute has received direct
funding and material support for this study from
Arthrex Inc. (Naples, Fl). The company had no influ-
ence on study design, data collection, and interpreta-
tion of the results or the writing of the final manuscript.
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